AstraZeneca ended a tie-up with Asher, and then set off on its own.

The FDA has cleared GSK’s drug again, after a no from the advisory committee.

The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials. 

The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.

Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.

But Perspective sinks again.